Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

Yvonne Brandberg; Hemming Johansson; Steinar Aamdal; Lars Bastholt; Michaela Hernberg; Ulrika Stierner; Hans von der Maase; Johan Hansson; Nordic Melanoma Cooperative Group

doi:10.3109/0284186X.2013.789140

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

Yvonne Brandberg, Hemming Johansson, Steinar Aamdal, Lars Bastholt, Michaela Hernberg, Ulrika Stierner, Hans von der Maase, Johan Hansson, Nordic Melanoma Cooperative Group

12 Citationer (Scopus)

Abstract

To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects.

Originalsprog	Engelsk
Tidsskrift	Acta oncologica
Vol/bind	52
Udgave nummer	6
Sider (fra-til)	1086-93
Antal sider	8
ISSN	0284-186X
DOI	https://doi.org/10.3109/0284186X.2013.789140
Status	Udgivet - aug. 2013

Adgang til dokumentet

10.3109/0284186X.2013.789140

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Brandberg, Y., Johansson, H., Aamdal, S., Bastholt, L., Hernberg, M., Stierner, U., von der Maase, H., Hansson, J., & Nordic Melanoma Cooperative Group (2013). Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta oncologica , 52(6), 1086-93. https://doi.org/10.3109/0284186X.2013.789140

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. / Brandberg, Yvonne; Johansson, Hemming; Aamdal, Steinar et al.
I: Acta oncologica , Bind 52, Nr. 6, 08.2013, s. 1086-93.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Brandberg, Y, Johansson, H, Aamdal, S, Bastholt, L, Hernberg, M, Stierner, U, von der Maase, H, Hansson, J & Nordic Melanoma Cooperative Group 2013, 'Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma', Acta oncologica , bind 52, nr. 6, s. 1086-93. https://doi.org/10.3109/0284186X.2013.789140

@article{5a235023c6ec4f488b8e6764b9b3fb7a,

title = "Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma",

abstract = "To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects.",

keywords = "Adolescent, Adult, Aged, Antineoplastic Agents, Chemotherapy, Adjuvant, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Interferons, Male, Melanoma, Middle Aged, Prognosis, Quality of Life, Questionnaires, Skin Neoplasms, Young Adult",

author = "Yvonne Brandberg and Hemming Johansson and Steinar Aamdal and Lars Bastholt and Michaela Hernberg and Ulrika Stierner and \{von der Maase\}, Hans and Johan Hansson and \{Nordic Melanoma Cooperative Group\}",

year = "2013",

month = aug,

doi = "10.3109/0284186X.2013.789140",

language = "English",

volume = "52",

pages = "1086--93",

journal = "Acta oncologica ",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "6",

}

TY - JOUR

T1 - Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

AU - Brandberg, Yvonne

AU - Johansson, Hemming

AU - Aamdal, Steinar

AU - Bastholt, Lars

AU - Hernberg, Michaela

AU - Stierner, Ulrika

AU - von der Maase, Hans

AU - Hansson, Johan

AU - Nordic Melanoma Cooperative Group

PY - 2013/8

Y1 - 2013/8

N2 - To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects.

AB - To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Interferons

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Prognosis

KW - Quality of Life

KW - Questionnaires

KW - Skin Neoplasms

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84880273462

U2 - 10.3109/0284186X.2013.789140

DO - 10.3109/0284186X.2013.789140

M3 - Journal article

C2 - 23621752

SN - 0284-186X

VL - 52

SP - 1086

EP - 1093

JO - Acta oncologica

JF - Acta oncologica

IS - 6

ER -